Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Thomas, George V, Tran, Chris, Mellinghoff, Ingo K, Welsbie, Derek S, Chan, Emily, Fueger, Barbara, Czernin, Johannes, Sawyers, Charles L·2006·Nature Medicine
DOI 10.1038/nm1337

Cited by (605)

Items 201–300 of 605

  1. Autophagy as a potential therapeutic target during epithelial to mesenchymal transition in renal cell carcinoma: An in vitro study
    Mamta Singla, Shalmoli Bhattacharyya · 2017 · Biomedicine & Pharmacotherapy
  2. Metformin synergistically suppress tumor growth with doxorubicin and reverse drug resistance by inhibiting the expression and function of P-glycoprotein in MCF7/ADR cells and xenograft models
    Ying Li, Meng Wang, Pei Zhi, Jian You, Jianqing Gao · 2017 · Oncotarget
  3. Recent Progress on Liver Kinase B1 (LKB1): Expression, Regulation, Downstream Signaling and Cancer Suppressive Function
    Ren‐You Gan, Hua‐Bin Li · 2014 · International Journal of Molecular Sciences
  4. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma
    Anil Kapoor, Robert A. Figlin · 2009 · Cancer
  5. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
    Didier Roulin, Laurent Waselle, Anne Dormond-Meuwly, Marc Dufour, Nicolas Demartines, Olivier Dormond · 2011 · Molecular Cancer
  6. HIF-1α and Cancer Therapy
    Mei Yee Koh, Taly R. Spivak-Kroizman, Garth Powis · 2009 · Recent results in cancer research/Recent Results in Cancer Research
  7. Imaging of tumor glucose utilization with positron emission tomography
    Andrea Bürkle, Wolfgang Weber · 2008 · Cancer and Metastasis Reviews
  8. CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma
    Shiruyeh Schokrpur, Junhui Hu, Diana L. Moughon, Peijun Liu, Lucia Christiana Lin, Kip J. Hermann, Serghei Mangul, Wei Guan, Matteo A. Pellegrini, Hua Xu et al. · 2016 · Scientific Reports
  9. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer
    Hong Xiang Zuo, Yong Jin, Zhe Wang, Ming Yue Li, Zhi Hong Zhang, Jing Ying Wang, Yue Xing, MyongHak Ri, Cheng Hua Jin, Guang Hua Xu et al. · 2020 · Journal of Ethnopharmacology
  10. Ginsenoside-Rg1 mediates a hypoxia-independent upregulation of hypoxia-inducible factor-1α to promote angiogenesis
    Kar Wah Leung, Hoi Man Ng, Maggie K. S. Tang, Chris K.C. Wong, Ricky Ngok‐Shun Wong, Alice S.T. Wong · 2011 · Angiogenesis
  11. AMPK regulates metabolism and survival in response to ionizing radiation
    Vanessa E. Zannella, Dan Cojocari, Susan Hilgendorf, Ravi Nagaraj Vellanki, Stephen Chung, Bradly G. Wouters, Marianne Koritzinsky · 2011 · Radiotherapy and Oncology
  12. Molecular Pathways in Renal Cell Carcinoma—Rationale for Targeted Treatment
    W KIM, W KAELINJR · 2006 · Seminars in Oncology
  13. Silibinin inhibits VEGF secretion and age‐related macular degeneration in a hypoxia‐dependent manner through the PI ‐3 kinase/ Akt / mTOR pathway
    Cheng‐Hui Lin, CH Li, PL Liao, LS Tse, WK Huang, H‐W Cheng, YW Cheng · 2012 · British Journal of Pharmacology
  14. Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: A feasibility study
    Angela A.W. van Baardwijk, Geert Bosmans, Robert Jan van Suylen, Marinus J.P.G. van Kroonenburgh, Monique M. H. Hochstenbag, Gijs G. Geskes, Philippe Lambin, Dirk De Ruysscher · 2008 · Radiotherapy and Oncology
  15. Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications
    Jehonathan H. Pinthus, Kaitlyn F. Whelan, Daniel Gallino, Jianping Lu, Nathan Rothschild · 2011 · Canadian Urological Association Journal
  16. Wilms' Tumor Protein Induces an Epithelial-Mesenchymal Hybrid Differentiation State in Clear Cell Renal Cell Carcinoma
    Valerie B. Sampson, Justin M. David, Isabel Puig, Pratima Patil, Antonio Garcı́a de Herreros, GEORGE V. THOMAS, Ayyappan K. Rajasekaran · 2014 · PLoS ONE
  17. Inhibitors of mTOR
    Heinz‐Josef Klümpen, Jos H. Beijnen, Howard Gurney, Jan H.M. Schellens · 2010 · The Oncologist
  18. Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma
    Jinhee Kim, Eric Jonasch, Angela Alexander, John D. Short, Shengli Cai, Sijin Wen, Dimitra Tsavachidou, Pheroze Tamboli, Bogdan A. Czerniak, Kim‐Anh Do et al. · 2008 · Clinical Cancer Research
  19. Malignant glioma drug discovery – targeting protein kinases
    Sith Sathornsumetee, Kaitlyn A Vredenburgh, Kathryn P. Lattimore, Jeremy N. Rich · 2007 · Expert Opinion on Drug Discovery
  20. A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma
    Natsuko Suwaki, Elsa Vanhecke, Katelyn M. Atkins, Manuela Graf, Kate Swabey, Paul H. Huang, Peter Schraml, Holger Moch, Amy R. Mulick, Daniel S. Brewer et al. · 2011 · Science Translational Medicine
  21. Defining Key Signaling Nodes and Therapeutic Biomarkers in NF1 -Mutant Cancers
    Clare F. Malone, Jody Fromm Longo, Ophélia Maertens, Thomas De Raedt, Rachel Ingraham, Karen M. Cichowski · 2014 · Cancer Discovery
  22. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy
    Sebastiano Buti, Alessandro Leonetti, Alice Dallatomasina, Melissa Bersanelli · 2016 · Core evidence
  23. HIF-1, an important regulator in potential new therapeutic approaches to ischemic stroke
    Sneha Vatte, Rajesh Ramesh Ugale · 2023 · Neurochemistry International
  24. Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors
    Sophie J. van Asselt, Sjoukje F. Oosting, Adrienne H. Brouwers, Alfons H.H. Bongaerts, Johan R. de Jong, Marjolijn N. Lub–de Hooge, Thijs H. Oude Munnink, Helle‐Brit Fiebrich, Wim J. Sluiter, Thera P. Links et al. · 2014 · Journal of Nuclear Medicine
  25. Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation
    Samira Alliouachene, Robyn L. Tuttle, Stéphanie Boumard, Thomas Lapointe, Sophie Bérissi, Stéphane Germain, Francis Jaubert, David Tosh, Morris J. Birnbaum, Mario Pende · 2008 · Journal of Clinical Investigation
  26. Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
    Elio Adib, Katarzyna Klonowska, Krinio Giannikou, Khanh T Do, Solida Pruitt-Thompson, Ketki Bhushan, Matthew I. Milstein, Jennifer Hedglin, Katherine E. Kargus, Lynette Marie Sholl et al. · 2021 · Clinical Cancer Research
  27. TORgeting oncogene addiction for cancer therapy
    Andrew Y. Choo, John Blenis · 2006 · Cancer Cell
  28. Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma
    Gary R. Hudes, Anna Berkenblit, Jay Marshall Feingold, Michael B. Atkins, Brian I. Rini, Janice P. Dutcher · 2009 · Seminars in Oncology
  29. Raptor-rictor axis in TGFβ-induced protein synthesis
    Falguni Das, Nandini Ghosh‐Choudhury, Lenin Mahimainathan, Balachandar A. Venkatesan, Denis Féliers, Daniel J. Riley, Balakuntalam S. Kasinath, Goutam Ghosh Choudhury · 2007 · Cellular Signalling
  30. S6K1 Plays a Key Role in Glial Transformation
    Jean L. Nakamura, Edna Garcia, Russell O. Pieper · 2008 · Cancer Research
  31. PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel
    Lin Yang, Michelle J. Clarke, Brett L. Carlson, Ann C. Mladek, Mark A. Schroeder, Paul A. Decker, Wenting Wu, Gaspar J. Kitange, Patrick Thomas Grogan, Jennie M. Goble et al. · 2008 · Clinical Cancer Research
  32. Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets
    Othon Iliopoulos · 2006 · Journal of Clinical Oncology
  33. Inhibition of hypoxia inducible factor by phenethyl isothiocyanate
    Xiuhong Wang, Breeze E. Cavell, Sharifah Sakinah Syed Alwi, Graham Packham · 2009 · Biochemical Pharmacology
  34. Exploiting the balance between life and death: Targeted cancer therapy and “oncogenic shock”
    Sreenath V. Sharma, Jeff Settleman · 2010 · Biochemical Pharmacology
  35. Crosstalk between HER2 signaling and angiogenesis in breast cancer
    Raafat S. Alameddine, Zaher K. Otrock, Ahmad Hussein Awada, Ali I. Shamseddine · 2013 · Current Opinion in Oncology
  36. Clinical implications of hypoxia inducible factor in renal cell carcinoma
    Marc C. Smaldone, Jodi Kathleen Maranchie · 2009 · Urologic Oncology Seminars and Original Investigations
  37. Contemporary treatment of metastatic renal cell carcinoma
    Paweł Wiechno, Jakub Kucharz, Małgorzata Sadowska, Wojciech Michalski, Bożena Sikora-Kupis, Joanna Jońska‐Gmyrek, Grażyna Poniatowska, Karol Nietupski, Krzysztof Ossoliński, Tomasz Demkow · 2018 · Medical Oncology
  38. Gambogic acid suppresses hypoxia‐induced hypoxia‐inducible factor‐1α/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3‐kinase/Akt/mammalian target protein of rapamycin pathway in multiple myeloma cells
    Fei Wang, Wei Zhang, Liting Guo, Wen Bao, Nan Jin, Ran Liu, Ping Liu, Yonghui Wang, Qinglong Guo, Baoan Chen · 2014 · Cancer Science
  39. HSP90 Supports Tumor Growth and Angiogenesis through PRKD2 Protein Stabilization
    Ninel Azoitei, Kristina Diepold, Cornelia Brunner, A. MAUREEN ROUHI, Felicitas Genze, Alexander Becher, Hans Armin Kestler, Johan Van Lint, Gabriela Chiosis, John Koren et al. · 2014 · Cancer Research
  40. Mutual Regulation of Hypoxia-Inducible Factor and Mammalian Target of Rapamycin as a Function of Oxygen Availability
    Karl Xaver Knaup, Katrin Jozefowski, Regina Schmidt, Wanja M. Bernhardt, Alexander Weidemann, Jan Steffen Jürgensen, Christina Warnecke, Kai‐Uwe Eckardt, Michael Sean Wiesener · 2009 · Molecular Cancer Research
  41. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors
    Matthew R. Zibelman, Yu‐Ning Wong, Karthik Devarajan, Lois Malizzia, Alycia Corrigan, Anthony J. Olszanski, Crystal Shereen Denlinger, Susan K. Roethke, Colleen H. Tetzlaff, Elizabeth R. Plimack · 2015 · Investigational New Drugs
  42. Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer
    Sharad S. Singhal, Archana Sehrawat, Mukesh Sahu, Preeti Singhal, Rit Vatsyayan, Poorna Chandra Rao Lelsani, Sushma Yadav, Sanjay Awasthi · 2009 · International Journal of Cancer
  43. Sequential use of targeted agents in the treatment of renal cell carcinoma
    Thomas E. Hutson, Ronald M. Bukowski, Charles Lance Cowey, Robert A. Figlin, Bernard J. Escudier, Cora Nanette Sternberg · 2010 · Critical Reviews in Oncology/Hematology
  44. PTEN suppression of YY1 induces HIF-2 activity in von hippel lindau null renal cell carcinoma
    Brenda L. Petrella, Constance Brinckerhoff · 2009 · Cancer Biology & Therapy
  45. FDG ‐ PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer
    James L. Chen, Daniel Appelbaum, Masha Kocherginsky, Charles Lance Cowey, W. Kimryn Rathmell, David F. McDermott, Walter Michael Stadler · 2013 · Cancer Medicine
  46. Hypoxic Tumors and Their Effect on Immune Cells and Cancer Therapy
    Patricia Yotnda, Danli Wu, Anna May Swanson · 2010 · Methods in molecular biology
  47. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin
    Andreas K.A. Gaumann, Hans Jürgen Schlitt, Edward Kenneth Geissler · 2008 · Transplant International
  48. Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy
    Arunkumar Anandharaj, Senthilkumar Cinghu, Woo‐Yoon Park · 2011 · Acta Biochimica et Biophysica Sinica
  49. Dimers of coumarin-1,2,3-triazole hybrids bearing alkyl spacer: Design, microwave-assisted synthesis, molecular docking and evaluation as antimycobacterial and antimicrobial agents
    D. Ashok, Srinivas Gundu, Vikas Kumar Aamate, Mohan Gandhi Devulapally, Raju Bathini, Vijjulatha Manga · 2017 · Journal of Molecular Structure
  50. mTOR pathway in renal cell carcinoma
    Sara C. Hanna, Samuel A. Heathcote, William Y. Kim · 2008 · Expert Review of Anticancer Therapy
  51. Nutrient Sensing in Cancer
    Margaret E. Torrence, Brendan D. Manning · 2017 · Annual Review of Cancer Biology
  52. Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma
    Arnulf Mayer, Fabienne Schneider, Peter W. Vaupel, Clemens Sommer, Heinz Schmidberger · 2012 · International Journal of Oncology
  53. Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel-7402/5-fluorouracil cells
    Sunbin Ling, Yu Tian, HAIQUAN ZHANG, KAIQI JIA, Tingting Feng, Deguang Sun, Zhenming Gao, Fei Xu, Zhaoyuan Hou, YAN LI et al. · 2014 · Molecular Medicine Reports
  54. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death
    Michael W. Ronellenfitsch, Daniel P. Brucker, Michael C. Burger, Stefan Wolking, Felix Tritschler, Johannes Rieger, Wolfgang Wick, Michael Weller, Joachim Peter Steinbach · 2009 · Brain
  55. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma
    Kyoichi Kaira, Masakuni Serizawa, Yasuhiro Koh, Toshiaki Takahashi, Hirofumi Hanaoka, Noboru Oriuchi, Masahiro Endo, Haruhiko Kondo, Takashi Nakajima, Nobuyuki Yamamoto · 2012 · European Journal of Cancer
  56. Hyperactivated JNK Is a Therapeutic Target in pVHL-Deficient Renal Cell Carcinoma
    Jiabin An, Huiren Liu, Clara E. Magyar, Yanchuan Guo, Mysore S. Veena, Eri S. Srivatsan, Jiaoti Huang, Matthew B. Rettig · 2013 · Cancer Research
  57. A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma
    Jingya Sun, Xin Wang, Boyun Tang, Hong‐Chun Liu, Minmin Zhang, Yueqin Wang, Fangfang Ping, Jian Ding, Aijun Shen, Meiyu Geng · 2018 · Theranostics
  58. Host mTORC1 Signaling Regulates Andes Virus Replication
    Shannon McNulty, Mike Flint, Stuart T. Nichol, Christina F. Spiropoulou · 2012 · Journal of Virology
  59. Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical Trials
    Janet Ellen Dancey, Rafael E. Curiel, Joseph D. Purvis · 2009 · Seminars in Oncology
  60. Temsirolimus: a safety and efficacy review
    R. Bukowski · 2012 · Expert Opinion on Drug Safety
  61. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma
    D. Tsavachidou-Fenner, Nizar M. Tannir, Pheroze Tamboli, W. Liu, David Petillo, Bin Tean Teh, Gordon Brent Mills, Eric Jonasch · 2010 · Annals of Oncology
  62. Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”
    Teresa Alonso‐Gordoa, Laura García‐Bermejo, Enrique Grande, Pilar Garrido, Alfredo Carrato, Javier Molina‐Cerrillo · 2019 · International Journal of Molecular Sciences
  63. On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy
    Janice P. Dutcher, Ronan Flippot, Jaleh Fallah, Bernard J. Escudier · 2020 · American Society of Clinical Oncology Educational Book
  64. Molecular Imaging: Reporter Gene Imaging
    Inna S. Serganova, Phillip Mayer-Kuckuk, Ruimin Huang, Ronald G. Blasberg · 2008 · Handbook of experimental pharmacology
  65. The Tuberous Sclerosis Complex Regulates Trafficking of Glucose Transporters and Glucose Uptake
    Xiuyun Jiang, Heidi L. Kenerson, Lauri D. Aicher, Robert S. Miyaoka, Janet F. Eary, John J. Bissler, Raymond S. W. Yeung · 2008 · American Journal Of Pathology
  66. Genetic diversity and selection of Tibetan sheep breeds revealed by whole-genome resequencing
    Dehong Tian, Buying Han, Xue Li, Dehui Liu, Baicheng Zhou, Chunchuan Zhao, Nan Zhang, Lei Wang, Quanbang Pei, Kai Zhao · 2023 · Animal Bioscience
  67. Pharmacokinetic Profile of Temsirolimus With Concomitant Administration of Cytochrome P450‐Inducing Medications1
    Joseph P Boni, Cathie A. Leister, Jaime Burns, Maria Cincotta, Bruce A. Hug, Laurence Moore · 2007 · The Journal of Clinical Pharmacology
  68. Synthesis and biological evaluation of novel N-substituted 1H-dibenzo[a,c]carbazole derivatives of dehydroabietic acid as potential antimicrobial agents
    Wen Gu, Chao Qiao, Shifa Wang, Yun Hao, Tingting Miao · 2013 · Bioorganic & Medicinal Chemistry Letters
  69. NCCN Task Force Report: mTOR Inhibition in Solid Tumors
    Robert A. Figlin, Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson, Harold J. Burstein, David S. Ettinger, Phillip G. Febbo, Matthew G. Fury, Gary R. Hudes et al. · 2008 · Journal of the National Comprehensive Cancer Network
  70. AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells?
    Madhumita Dandapani, David Grahame Hardie · 2013 · Biochemical Society Transactions
  71. Hypoxia-inducible factor-1alpha: A promising therapeutic target in endometriosis
    Lei Zhan, Wenyan Wang, Yu Zhang, Enxue Song, Yijun Fan, Bing Wei · 2016 · Biochimie
  72. Cinobufagin suppresses colorectal cancer angiogenesis by disrupting the endothelial mammalian target of rapamycin/hypoxia‐inducible factor 1α axis
    Xiaowu Li, Chunhui Chen, Yu Dai, Chengzhi Huang, Qinrui Han, Linlin Jing, Ye Ma, Yihua Xu, Yawei Liu, Liang Zhao et al. · 2019 · Cancer Science
  73. The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial–mesenchymal transition induced by hypoxia and TGF-β1
    Guanyu Lin, Renhua Gai, Zibo Chen, Yijie Wang, Sida Liao, Rong Dong, Hong Zhu, Yongchuan Gu, Qiaojun He, Bo Yang · 2014 · European Journal of Pharmacology
  74. Regulation of mTORC1 Signaling by Src Kinase Activity Is Akt1-Independent in RSV-Transformed Cells
    Martina Vojtěchová, Jolana Turečková, Dana Kučerová, Eva Šloncová, J Vachtenheim, Zdena Tuháčková · 2008 · Neoplasia
  75. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: An in vivo bioluminescence imaging study
    Qing Zeng, Zhong Hui Yang, Yong‐Jing Gao, Huaiping Yuan, Kemi Cui, Ying Shi, Hongyun Wang, Xudong Huang, Stephen T. C. Wong, Yaming Wang et al. · 2010 · European Journal of Cancer
  76. A Retroinhibition Approach Reveals a Tumor Cell–Autonomous Response to Rapamycin in Head and Neck Cancer
    Panomwat Amornphimoltham, Vyomesh Patel, Kantima Leelahavanichkul, Robert T. Abraham, Jorge Silvio Gutkind · 2008 · Cancer Research
  77. Co-Delivery of Metformin Enhances the Antimultidrug Resistant Tumor Effect of Doxorubicin by Improving Hypoxic Tumor Microenvironment
    Ying Li, Jing Luo, Mengting Lin, Pei Zhi, Wang-Wei Guo, Min Young Han, Jian You, Jianqing Gao · 2019 · Molecular Pharmaceutics
  78. Cordycepin and kinase inhibition in cancer
    Md. Asaduzzaman Khan, Mousumi Tania · 2022 · Drug Discovery Today
  79. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
    Charles Swanton, James Larkin, Marco Gerlinger, Aron Charles Eklund, Michael T. Howell, Gordon Stamp, Julian Downward, Martin Eric Gore, P. Andrew Futreal, Bernard J. Escudier et al. · 2010 · Genome Medicine
  80. Oxygen-dependent changes in binding partners and post-translational modifications regulate the abundance and activity of HIF-1α/2α
    Leonard A. Daly, Philip Brownridge, Michael Batie, Sónia Rocha, Violaine Sée, Claire E. Eyers · 2021 · Science Signaling
  81. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer
    Jan C. Buckner, Bahram Forouzesh, Charles Erlichman, Manuel M. Hidalgo, Joseph P Boni, Gary Dukart, Anna Berkenblit, Eric Keith Rowinsky · 2009 · Investigational New Drugs
  82. Radiosensitization of renal cell carcinoma in vitro through the induction of autophagy
    Selvakumar Anbalagan, Isabel M. Pires, Christopher Blick, Mark A. Hill, David J. P. Ferguson, Denise A. Chan, Ester M. Hammond · 2012 · Radiotherapy and Oncology
  83. Complex cellular functions of the von Hippel–Lindau tumor suppressor gene: insights from model organisms
    Tien Hsu · 2011 · Oncogene
  84. Morphogenomics and Morphoproteomics: A Role for Anatomic Pathology in Personalized Medicine
    Robert Eldon Brown · 2009 · Archives of Pathology & Laboratory Medicine
  85. Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus
    Julien Hadoux, Stéphane Vignot, Thibault De La Motte Rouge · 2010 · Clinical Medicine Insights Oncology
  86. A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
    Kevin Dale Courtney, Judith B. Manola, Aymen A. Elfiky, Robert W. Ross, William K. Oh, Jeffrey T. Yap, Annick D. Van den Abbeele, Christopher W. Ryan, Tomasz M. Beer, Massimo F. Loda et al. · 2014 · Clinical Genitourinary Cancer
  87. Celastrol inhibits the HIF-1α pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells
    MA, JUAN, HAN, LI ZHUO, LIANG, HE, MI, CHUNLIU, SHI, HUI, LEE, JUNG JOON, JIN, XUEJUN · 2014 · Oncology Reports
  88. Biologic correlates of 18F-FDG uptake on PET in pulmonary pleomorphic carcinoma
    Kyoichi Kaira, Masahiro Endo, Masato Abe, Kazuo Nakagawa, Yasuhisa Ohde, Takehiro Okumura, Toshiaki Takahashi, Haruyasu Murakami, Asuka Tsuya, Yukiko Nakamura et al. · 2010 · Lung Cancer
  89. Energy sensing pathways: Bridging type 2 diabetes and colorectal cancer?
    Juhong Yang, Reiko Nishihara, Xuehong Zhang, Shuji Ogino, Zhi Rong Qian · 2017 · Journal of Diabetes and its Complications
  90. Unrestrained Mammalian Target of Rapamycin Complexes 1 and 2 Increase Expression of Phosphatase and Tensin Homolog Deleted on Chromosome 10 to Regulate Phosphorylation of Akt Kinase
    Falguni Das, Nandini Ghosh‐Choudhury, Nirmalya Dey, Chandi Charan Mandal, Lenin Mahimainathan, Balakuntalam S. Kasinath, Hanna E. Abboud, Goutam Ghosh Choudhury · 2011 · Journal of Biological Chemistry
  91. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer
    Armina A. Kazi, Rabia Afzal Gilani, Amanda J. Schech, Saranya Chumsri, Gauri J. Sabnis, Preeti Shah, Olga G. Goloubeva, Shari S. Kronsberg, Angela Brodie · 2014 · Breast Cancer Research
  92. Hypoxia Inducible Factor 1 Alpha Is Expressed in Germ Cells throughout the Murine Life Cycle
    Natsumi Takahashi, Philip M. C. Davy, Lauren H. Gardner, Juanita Mathews, Yuki Yamazaki, Richard Allsopp · 2016 · PLoS ONE
  93. Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
    Faes, Seraina, Demartines, Nicolas, Dormond, Olivier · 2021 · Frontiers in Cell and Developmental Biology
  94. Activation of HIF‐1α in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway
    Dayan, Frédéric, Bilton, Rebecca L., Laferrière, Julie, Trottier, Eric, Roux, Danièle, Pouyssegur, Jacques, Mazure, Nathalie. M. · 2009 · Journal of Cellular Physiology
  95. Renal cancer: signaling pathways and advances in targeted therapies
    Aimin Jiang, Jinxin Li, Ziwei He, Ying Liu, Kun Qiao, Yu Fang, Le Qu, Peng Luo, Anqi Lin, Linhui Wang · 2024 · MedComm
  96. Natural Products in Drug Discovery: Impacts and Opportunities — An Assessment
    Goutam Brahmachari · 2011 · WORLD SCIENTIFIC eBooks
  97. Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies
    Michaël G. Magagnin, Marianne Koritzinsky, Bradly G. Wouters · 2006 · Drug Resistance Updates
  98. Rapamycin Inhibits In Vitro Growth and Release of Angiogenetic Factors in Human Bladder Cancer
    Guido Fechner, Katarina Claßen, Doris H. Schmidt, Stefan Hauser, Stefan C. Müller · 2008 · Urology
  99. Molecular imaging agents: impact on diagnosis and therapeutics in oncology
    Marc E. Seaman, Gianmarco Contino, Nabeel M. Bardeesy, Kimberly A. Kelly · 2010 · Expert Reviews in Molecular Medicine
  100. Synthetic lethality-based targets for discovery of new cancer therapeutics.
    Ulrich H. Weidle, Daniela Maisel, Dirk Eick · 2011 · PubMed